key: cord-0298602-j2d2jga5 authors: hoque, a.; Rahman, M.; Imam, H.; Nahar, N.; Hasan Chowdhury, F. U. title: Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infections date: 2021-11-09 journal: nan DOI: 10.1101/2021.11.08.21266037 sha: 5561593a4265d1e0d25edeb35f1828318a5aa1f8 doc_id: 298602 cord_uid: j2d2jga5 Background: Breakthrough events are not rare after emerging of the Delta variant. On the other hand, long COVID is an unsolved issue where sufferers suffer a lot. Some study has shown that the COVID-19 vaccine has improved some clinical and libratory parameters in long COVID. But what will be the possible measures against long COVID after the breakthrough event is still a burning question. Method: We have observed the third dose by BNT162b2 in a small group(n=20) who were diagnosed as long COVID after breakthrough infections, in Sheikh Hasina National Institute of Burn & Plastic Surgery Institute, Dhaka, Bangladesh. CRP(C-reactive protein) and Anti S1 RBD IgG responses were measured. Result: All 20 participants in the study received both dosages of ChAdOx1-nCoV-19 between February 2021 to April 2021 and had breakthrough infections in the same or following month which led to long COVID syndrome. They all received a third dose of BNT162b2. A before and after 3rd dose (14 days after) CRP from participants' serum was measured. A Wilcoxon matched paired signed-rank test revealed a significant (P-value <0.05) reduction of inflammatory marker (CRP) after receiving the 3rd vaccine dose. Pre and post 3rd dose quantitative anti-S1-RBD IgG response was measured and compared that revealed a significant boosting effect that clearly correlates with the CRP response. Conclusion: Coverage of vaccines all over the world is still not expected level to control this pandemic. WHO has not recommended the use of a third/booster dose of COVID vaccines. Though our results show some sort of hope for the long COVID in breakthrough events after getting the third dose more study is needed to conclude this issue. dose of COVID vaccines. Though our results show some sort of hope for the long COVID in breakthrough events after getting the third dose more study is needed to conclude this issue. Key words: Breakthrough infection, Long COVID, CRP. From the beginning of COVID-19 spreads around the globe, it is mutating, which means it is acquiring genetic changes. This change has made vaccines difficult to combat and control the pandemic scenario. In the trial results of the vaccine, we have found that it can reduce hospital admission to a great is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.08.21266037 doi: medRxiv preprint following initial recovery from an acute COVID-19 episode or persist from the initial illness. Symptoms may also fluctuate or relapse over time 3 . CDC's has defined a breakthrough infection as a COVID case that occurs in someone who is fully vaccinated, meaning 14 or more days after completing the recommended doses of an authorized vaccine. No specific protocol is yet to be found to treat long COVID. Pharmacological management is still not good enough to cure it. We want to evaluate the role of the third dose of COVID vaccine in patients suffering from long COVID after breakthrough infection. This observational study was conducted at Sheikh Hasina National Institute of Burn and Plastic Surgery, Dhaka February 2021 to October 2021. We enrolled 20 participants for our study who received both doses of ChAdOx1-nCoV-19 of the vaccine in the initial rollout of a vaccine in the country (February to April) and had breakthrough infection in the same or following month which led to long COVID syndrome. Participants' demographic data along with past SARS-COV-2 infection history and existing comorbidities were recorded using a structured questionnaire. Serological testing for CRP was done by Invitrogen is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.08.21266037 doi: medRxiv preprint and standard deviation or median and interquartile ranges, as appropriate. Categorical variables are reported as counts and percentages. The analysis was performed in Graphpad Prism 9.0. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.08.21266037 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.08.21266037 doi: medRxiv preprint may associate risk factors may include. More research is needed to establish such risk factors 4 . One known aspect of long COVID is that similar post viral syndrome was observed with prior human corona virus diseases. For example, symptoms of fatigue, myalgia, and psychiatric impairments have inflicted survivors of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) for up to four years [5] [6] [7] [8] [9] . Even at 7-year and 15-year follow-ups, pulmonary and bone radiological complications were still evident among a proportion of SARS survivors who were mostly younger than 40 years 10, 11 . A review has proposed that T-cells dysfunction may promote long COVID pathophysiology similarly in autoimmune diseases 12 . B-cells may also be involved in long COVID autoimmunity. In a study analysing serum samples from hospitalized COVID-19 patients, antiphospholipid, autoantibodies were detected in 52% of samples, which were further associated with neutrophil hyperactivity and more severe clinical outcomes 14 . Besides, evidence exists that severe COVID-19 causes lymphopenia (i.e. B-cell and T-cell lymphocytes deficiency) that causes hyperinflammation 15, 16 . This is because lymphocytes, particularly T-cells, participate in inflammation resolution following infection 17, 18 . Meta-analyses have determined lymphopenia and high pro-inflammatory neutrophil count as independent risk factors of COVID-19 severity and mortality [19] [20] [21] . Thus, as B- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.08.21266037 doi: medRxiv preprint cell and T-cell lymphocytes are renewed, elevated inflammation from unresolved hyper inflammation may ensue and contribute to longCOVID [22] [23] [24] . with persistent SARS-CoV-2 shedding, which may further perpetuate chronic immune activation in long COVID 25, 26 . Residual inflammation from post-SARS-CoV-2 could lead to long COVID in adults. Raised pro-inflammatory markers (e.g. CRP, IL-6, and D-dimer) and lymphopenia have been associated with long COVID. Other studies have shown that COVID-19 pulmonary lesions at two-month post-admission were associated with elevated systemic inflammatory biomarkers, such as D-dimer, interleukin-6 (IL-6), and CRP 27, 28 . A study showed, increased D-dimer and CRP levels and decreased lymphocytes were more common in COVID-19 survivors who developed persistent symptoms than their fully recovered counterparts 29 . Response to infections, liver synthesizes significant quantities of acute-phase proteins (APPs), such as CRP 30, 31 . Acute inflammatory protein is a highly sensitive biomarker for inflammation, tissue damage, and infection 32 . Different result has shown that CRP levels are correlated with levels of inflammation 33 . CRP levels can promote phagocytosis and activate the complement system 34 . In other words, CRP binds to microorganisms and promotes their removal through phagocytosis 35 . Long COVID SOS a survey conducted by UK advocacy group, the University of Exeter, and the University of Kent which showed 57% of participants experienced at least some improvement in symptoms after a vaccine when they were affected by long COVID. Less than 7% have experienced deteriorating is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; https://doi.org/10.1101/2021.11.08.21266037 doi: medRxiv preprint symptoms. Though all vaccines showed benefits they have said mRNA vaccine improved the scenario most. One of the possible hypotheses behind the improvement after getting the vaccine is, persistent infection causes long-haulers to feel sick, and then the vaccine shot might be helping their immune system finally clear the virus. Another possible theory is that vaccines might rev up a person's immune system and shift the sufferers back into a steady state of equilibrium. In our study, we have found a dramatic improvement in CRP value which was higher than normal after getting COVID several months back. Their Ct values of rt-PCR were persistently around 36. These changes can be a possibility of immune boost up after the third dose of vaccine which initiates viral clearance from the body. Quantitative assessments of antibodies (IgG) were raised after getting the third dose. According to these two results with their improvement of symptoms, we hypothesize that the third dose with BNT162b2 might clear the residual viral load as it could halt the ongoing inflammatory process initiated by breakthrough infections. This short sample size cannot produce generalizability. Therefore, subsequent clinical studies with larger sample sizes with different age group should be enclosed to confirm our findings. The third dose is still not recommended by most the country in the world as well as WHO as vaccines are not sufficient according to the demand of pandemics. Few countries like the USA approved the third dose to combat . CC-BY-ND 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted November 9, 2021. ; COVID-19 Interactive Data Dashboard Outbreakof SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated withlarge public gatherings-Barnstable County Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments Follow-up chest radiographic findings in patients with MERS-CoV after recovery Depression as a Mediatorof Chronic Fatigue and Post-Traumatic Stress Symptoms in Middle East Respiratory Syndrome Survivors Mental morbidities and chronic fatigue in severeacute respiratory syndrome survivors: long-term follow-up The long-term impact ofsevere acute respiratory syndrome on pulmonary function, exercise capacity, and health status Psychiatric andneuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysiswith comparison to the COVID-19 pandemic Long-term bone and lung consequences associated with hospitalacquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study Osteonecrosis of the femoral headin SARS patients: seven years later The knownunknowns of T cell immunity to COVID Covid-19 andautoimmunity Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Lymphopenia in COVID-19: therapeuticopportunities Lymphopenia during the COVID-19 infection: What itshows and what can be learned Dynamic changes oflymphocyte counts in adult patients with severe pandemic H1N1 influenza A Higher level of neutrophilto-lymphocyte is associated with severe COVID-19 A meta-analysisof potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19) Biomarkers and outcomesof COVID-19 hospitalisations: systematic review and metaanalysis Risk factors of severe cases withCOVID-19: a meta-analysis Lymphopenia during the COVID-19 infection: What itshows and what can be learned Dynamic changes oflymphocyte counts in adult patients with severe pandemic H1N1 influenza A Higher level of neutrophilto-lymphocyte is associated with severe COVID-19 A compromised specifichumoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence andperiodic shedding in the gastrointestinal tract Reduced numbers of T cellsand B cells correlates with persistent SARS-CoV-2 presencein non-severe COVID-19 patients First report on clinical and radiological features of COVID-19 pneumonitis ina Caucasian population: Factors predicting fibrotic evolution Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator ofpersistent pulmonary injury in COVID-19 Long-COVID': a crosssectional study of persisting symptoms, biomarker andimaging abnormalities following hospitalisation for COVID Types of acute phase reactants and their importance in vaccination Validity of C-reactive protein and procalcitonin in prediction of bacterial infection in patients with liver cirrhosis Role of C-reactive protein at sites of inflammation and infection Diagnostic utility of CRP to neopterin ratio in patients with acute respiratory tract infections C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an anti-inflammatory innate immune response C-reactive protein: structure, synthesis and function,‖ C-Reactive Protein: New Research, 2009.View at: Publisher Site | Google Scholar against emerging Delta variant. Long COVID is a very notorious condition that has no proper solution to date. From our study, we can hope that the third dose with mRNA vaccine could be an option to control it. More data is needed to conclude this issue. The authors have declared no competing interests. No external funding was received. I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.